Radiometric temperature analysis of the Hayabusa spacecraft re-entry

Hayabusa, an unmanned Japanese spacecraft, was launched to study and collect samples from the surface of the asteroid 25143 Itokawa. In June 2010, the Hayabusa spacecraft completed it’s seven year voyage. The spacecraft and the sample return capsule (SRC) re-entered the Earth’s atmosphere over the central Australian desert at speeds on the order of 12 km/s. This provided a rare opportunity to experimentally investigate the radiative heat transfer from the shock-compressed gases in front of the sample return capsule at true-flight conditions. This paper reports on the results of observations from a tracking camera situated on the ground about 100 km from where the capsule experienced peak heating during re-entry

Rubidium atomic funnel

A low-velocity beam of rubidium atoms is produced from a two-dimensional magneto-optic trap or atomic funnel. Atoms from a thermal beam are slowed by chirped laser cooling and then loaded into the funnel. The cold atoms are ejected by moving molasses formed with frequency-shifted laser beams. The resultant atomic beam has a controllable velocity in the range of 3 to 10 m/s, a temperature of 500 μK, and a flux of 1010 atoms/s

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials

<p>Abstract</p> <p>Background</p> <p>Asenapine demonstrated superiority over placebo for mania in bipolar I disorder patients experiencing acute current manic or mixed episodes in 2 randomized, placebo-and olanzapine-controlled trials. We report the results of exploratory pooled post hoc analyses from these trials evaluating asenapine's effects on depressive symptoms in patients from these trials with significant baseline depressive symptoms.</p> <p>Methods</p> <p>In the original trials (A7501004 [NCT00159744], A7501005 [NCT00159796]), 977 patients were randomized to flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter), placebo, or oral olanzapine 5-20 mg once daily for 3 weeks. Three populations were defined using baseline depressive symptoms: (1) Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥20 (n = 132); (2) Clinical Global Impression for Bipolar Disorder-Depression (CGI-BP-D) scale severity score ≥4 (n = 170); (3) diagnosis of mixed episodes (n = 302) by investigative site screening. For each population, asenapine and olanzapine were independently compared with placebo using least squares mean change from baseline on depressive symptom measures.</p> <p>Results</p> <p>Decreases in MADRS total score were statistically greater with asenapine versus placebo at days 7 and 21 in all populations; differences between olanzapine and placebo were not significant. Decreases in CGI-BP-D score were significantly greater with asenapine versus placebo at day 7 in all categories and day 21 in population 1; CGI-BP-D score reductions were significantly greater with olanzapine versus placebo at day 21 in population 1 and day 7 in populations 2 and 3.</p> <p>Conclusions</p> <p>These post hoc analyses show that asenapine reduced depressive symptoms in bipolar I disorder patients experiencing acute manic or mixed episodes with clinically relevant depressive symptoms at baseline; olanzapine results appeared to be less consistent. Controlled studies of asenapine in patients with acute bipolar depression are necessary to confirm the generalizability of these findings.</p

12-Month progression of motor and functional outcomes in congenital myotonic dystrophy

Background: We aim to describe 12-mo functional and motor outcome performance in a cohort of participants with congenital myotonic dystrophy (CDM). Methods: CDM participants performed the 6 Minute Walk Test (6MWT), 10 Meter Run, 4 Stair Climb, Grip Strength, and Lip Force at baseline and 12-mo visits. Parents completed the Vineland Adaptive Behavior Scale. Results: Forty-seven participants, aged 0 to 13 y old, with CDM were enrolled. 6MWT, 10 Meter Run, and 4 Stair Climb were completed in \u3e85% of eligible participants. The only significant difference between mean baseline and 12-mo performance was an improvement in 6MWT in children 3-6 y old (P =.008). This age group also had the largest mean % improvement in performance in all other timed functional testing. In children \u3e7 y, the slope of change on timed functional tests decreased or plateaued, with further reductions in performance in children ≥10 y. Participants with CTG repeat lengths \u3c500 did not perform differently than those with repeat lengths \u3e1000. Conclusions: The 6MWT, 10 Meter Run, and 4 Stair Climb were the most feasible measures. Our findings are consistent with the clinical profile and prior cross-sectional data, helping to establish reasonable expectations of functional trajectories in this population as well as identifying points in which therapeutic interventions may be best studied. Further study of outcomes in children \u3e10 y old and \u3c3 y is warranted, but this new information will assist planning of clinical trials in the CDM population

Development of magnetorheological elastomers (MREs) for strength and fatigue resistance

Natural rubber (NR)-based magnetorheological elastomers (MREs) exhibiting a reasonable switching effect were fabricated and tested. They were strong enough for use in automotive applications but still needed protection against ageing. Ethylene–propylene–diene rubber (EPDM) is a cost-effective material that is frequently used in the automotive industry because of its advantageous range of properties. With these applications in mind, it was a logical progression to the development of EPDM-based MREs. Unlike strain-crystallising NR, EPDM requires reinforcement to render its tensile and fatigue strength suitable for use in most applications. While small amounts of carbon black were sufficient for the NR-based MREs, a trade-off between non-reinforcing carbonyl iron powder (CIP) and reinforcing carbon black fillers was necessary to imbue the EPDM-based MREs with reasonably good mechanical properties. With a limit on the quantities of fillers that could be added, attention was turned to the matrix material itself and the blend of polymers employed in EPDM2 and EPDM3 were chosen in order to strengthen the EPDM-based MREs by enhancing polymer molecular weight and reinforcement. However, an unwanted effect of the stronger polymer network was the high-viscosity matrix in these compounds which hindered the alignment of magnetic particles early in the vulcanisation process. This led to poorer magnetic particle orientation, resulting in a more homogenous dispersion of the CIP and consequently produced MRE specimens that were more isotropic than anisotropic. Subsequently the switching effect of these materials was lower than would be obtained in MREs with a low viscosity (say, 40 MU) matrix. It was not feasible to sacrifice reinforcing carbon black in these compounds, but there are other possibilities open to the rubber compounder. An alternative means of reducing the viscosity of EPDM3 is simply to double the content of softening oil. This would have a slight but minimal negative effect on the tensile properties of the material. The addition of a small amount of retardant to delay vulcanisation and extend the time available for orientation of the magnetic particles into chains would also be beneficial. This would also reduce the modulus of the compound, but the reduction would again be negligible. As in all material design, there is a trade-off to be made in choosing the right combination of properties, but both of these changes would result in the development of an effective magnetorheological compound

Common data elements to standardize genomics studies in cerebral palsy

Aim To define clinical common data elements (CDEs) and a mandatory minimum data set (MDS) for genomic studies of cerebral palsy (CP). Method Candidate data elements were collated following a review of the literature and existing CDEs. An online, three-round Delphi survey was used to rate each data element as either ‘core’, ‘recommended’, ‘exploratory’, or ‘not required’. Members of the International Cerebral Palsy Genomics Consortium (ICPGC) rated the core CDEs as either mandatory or not, to form the MDS. For both the CDEs and the MDS, a data element was considered to have reached consensus if more than 75% of respondents agreed. Results Forty-six individuals from around the world formed the Delphi panel: consumers (n=2), scientists/researchers (n=17), medical (n=19), and allied health professionals (n=8). The CDEs include 107 data elements across six categories: demographics, diagnostics, family history, antenatal and neonatal details, clinical traits, and CP-specific assessments. Of these, 10 are mandatory, 42 core, 41 recommended, and 14 are exploratory. Interpretation The ICPGC CDEs provide a foundation for the standardization of phenotype data captured in CP genomic studies and will benefit international collaborations and pooling of data, particularly in rare conditions

Report of the ICES\NAFO Joint Working Group on Deep-water Ecology (WGDEC), 11–15 March 2013, Floedevigen, Norway.

On 11 February 2013, the joint ICES/NAFO WGDEC, chaired by Francis Neat (UK) and attended by ten members met at the Institute for Marine Research in Floedevi-gen, Norway to consider the terms of reference (ToR) listed in Section 2. WGDEC was requested to update all records of deep-water vulnerable marine eco-systems (VMEs) in the North Atlantic. New data from a range of sources including multibeam echosounder surveys, fisheries surveys, habitat modelling and seabed imagery surveys was provided. For several areas across the North Atlantic, WGDEC makes recommendations for areas to be closed to bottom fisheries for the purposes of conservation of VMEs